• Proceedings of the PSK Conference
• /
• 2002.10a
• /
• pp.201-205
• /
• 2002

It is generally accepted that the immune system is one of the major target organs for many toxic chemicals. In addition, many toxic chemicals require metabolic activation by cytochrome P450s for their toxicity. Although the immune cells possess a limited amount of drug metabolizing capacity, metabolic activation of certain toxicants in liver and immune organs may have a significant role in immunosuppression. In the present studies, the possible role of metabolic activation by cytochrome P450s in chemical-induced immunosuppression was reviewed, with a particular emphasis on the methodological techniques to detect immunotoxicants requiring metabolic activation in vivo and in vitro. (omitted)

• IMMUNE NETWORK
• /
• v.10 no.3
• /
• pp.85-91
• /
• 2010

As a nanotechnology has been actively applied to the overall areas of scientific fields, it is necessary to understand the characteristic features, physical behaviors and the potential effects of exposure to nanomaterials and their toxicity. In this article we review the immunological influences induced by several nanomaterials and emphasize establishment of the animal models to estimate the impact of these nanomaterials on development of immunological diseases.

• Journal of Yeungnam Medical Science
• /
• v.38 no.4
• /
• pp.366-370
• /
• 2021

Immune checkpoint inhibitors (ICIs) have become the main drugs for programmed cell death receptor-1 or ligand-1 expressing non-small cell lung cancer (NSCLC) combined with conventional chemotherapy. ICIs are generally more tolerable than cytotoxic chemotherapies in terms of toxicity, and ICI-related adverse events are mild and manageable. However, these drugs may lead to unexpected severe adverse events such as immune-related hematologic toxicities, which could be life-threatening. Here, a rare case of a pembrolizumab-related adverse event in a patient with NSCLC who showed early-onset hemolytic anemia and recovered by high-dose steroid and a series of plasma exchanges is reported.

• IMMUNE NETWORK
• /
• v.15 no.2
• /
• pp.58-65
• /
• 2015

Melanoma is the most aggressive skin cancer and its incidence is gradually increasing worldwide. Patients with metastatic melanoma have a very poor prognosis (estimated 5-year survival rate of <16%). In the last few years, several drugs have been approved for malignant melanoma, such as tyrosine kinase inhibitors and immune checkpoint blockades. Although new therapeutic agents have improved progression-free and overall survival, their use is limited by drug resistance and drug-related toxicity. At the same time, adoptive cell therapy of metastatic melanoma with tumor-infiltrating lymphocytes has shown promising results in preclinical and clinical studies. In this review, we summarize the currently available drugs for treatment of malignant melanoma. In addition, we suggest cytokine-induced killer (CIK) cells as another candidate approach for adoptive cell therapy of melanoma. Our preclinical study and several previous studies have shown that CIK cells have potent anti-tumor activity against melanomas in vitro and in an in vivo human tumor xenograft model without any toxicity.

• Korean Journal of Oriental Medicine
• /
• v.8 no.2 s.9
• /
• pp.109-119
• /
• 2002

The objective on this study was to investigate effect of KH, which was composed of 9 kinds of oriental herbs tonifing the blood, against toxicity of 5-flurouracil(FU) through animal study. Reduction of WBC and platelet after treating S-FU was significantly recovered by KH. KH also rehabilitated immune gene expression of interleukin-2(IL2) and $Interferon-{\gamma}\;(IFN-{\gamma})$ by RT-PCR. In addition, in situ hybridization of spleen showed that KH treatment increased mRNA expression of IL2. In addition to the immune action, antitumor activity on 5-FU was not affected by KH treatment. In conclusion, our study demonstrated that KH alleviated damage of hematopoiesis system induced by f-FU without toss of antitumor activity.

• Asian-Australasian Journal of Animal Sciences
• /
• v.18 no.6
• /
• pp.898-907
• /
• 2005

Chromium has emerged as an essential trace mineral in nutrition. However, it readily causes toxicity because of slightly excessive dose and/or form of chromium supplement. Therefore, developing a noble form of chromium supplement which is capable of not only an increased availability but also a reduced toxicity has been a critical issue in chromium nutrition. Chromium-methionine chelate has been, so far, one of the latest developments in its kind. Although not much information is available for the chromium-methionine chelate, especially in view of animal performances upon dietary supplementation, several studies indicated chromium methionine chelate could be effective to improve meat quality by increasing muscle mass but decreasing body fat. Highly-graded beef was produced by dietary chromium methionine supplementation during fattening stage of Korean native steers. Body muscle was increased in replace of decreasing body fat in both pig and rat that were dietary supplemented with chromium methionine chelate. However, a pig farm study did not show any significant improvement of body gain upon supplementation of chromium methionine. Immune responses of pig and rat were not always dependent upon chromium form but were varied by species. These results suggest there could be a different mode of responses due to species as well as onset time of dietary supplementation of chromium methionine. It is still early to conclude the bio-efficacy of chromium methionine chelate presumably due to its recent appearance into the field. But the chelate is certainly worth more application to animal since it certainly reduced the application level of dietary chromium.

• Herbal Formula Science
• /
• v.16 no.1
• /
• pp.147-168
• /
• 2008

HYTE (Hyeonggaeyeongyotang Extract), a polyherbal formula has been used as folk medicine, 28days repeat oral dose toxicity was tested in SD rats according to KFDA Guideline[2005-60]. Methods : In this study, mortality, clinical signs, body weight and gains, food and water consumption, ophthalmologic observation, urinalysis, hematology, serum biochemistry, gross findings, organ weight and histopathological observations were conducted during 28days of dosing periods. Results: 1. No HYTE treatment-related mortalities and clinical signs were detected in all dosing levels tested in male and female rats during the whole experimental periods. 2. No HYTE treatment-related changes on body weight, gains and food consumption were detected in all dosing levels tested in male and female rats during the whole experimental periods except for 2000mg/kg-dosing female groups in which significantly increase of body weight, gains, food and water consumption were detected compared to that of vehicle control in some points. 3. No HYTE treatment-related changes on ophthalmologic examination were detected in all dosing levels tested in male and female rats. 4. No HYTE treatment-related changes on urinalysis were detected in all dosing levels tested in male and female rats except for 2000mg/kg-dosing female groups in which, significantly increase of urine volume and related decrease on the urine specific gravity were detected as secondary effects of increase on the water consumptions not HYTE treatment-related toxicological signs. 5. No HYTE treatment-related changes on hematology were detected in all dosing levels tested in male and female rats except for increases in the total WBC count and lymphocytes of 2000mg/kg-dosing male and female groups with decrease of large unstained cells as pharmacological effects of immune enhancements not HYTE treatment-related toxicological signs. 6. No HYTE treatment-related changes on serum biochemistry were detected in all dosing levels tested in male and female rats. 7. No HYTE treatment-related changes on gross findings, organ weight and histopathology were detected in all dosing levels tested in male and female rats except for 2000mg/kg-dosing male and female groups in which, spleen and thymus organ weights, hypertrophy at gross observation and hyperpalsia of lymphoid cells and follicles at histopathological observation in spleen and thymus were detected as pharmacological effects of immune enhancements not HYTE treatment-related toxicological signs. Conclusions : Based on these results, the NOAEL and MTD of HYTE in SD rats were considered as over 2000mg/kg, respectively at 28days repeat oral dose toxicity test because most of these findings were considered as results of pharmacological effects of immune enhancements not HYTE treatment-related toxicological signs or secondary effects.

• The Journal of Internal Korean Medicine
• /
• v.28 no.4
• /
• pp.671-680
• /
• 2007

Objectives : The purpose of this study was to examine the effect of Haeyeol-tang on infectious disease of respiratory system. Methods : Haeyeol-tang was used by cold storage after dilution with 1, 10 and $100{\mu}g/ml$ of PBS, from dried material as extracted material with extraction with 50% ethanol. Statistical significance was examined through measuring TNF-$\alpha$, RT-PCR, DPPH, nitric oxide(NO), and MTT of Raw264.7 cells activated with LPS. Results : For the toxicity experiment of Haeyeol-tang, almost no toxicity was shown on cells in the concentration ranges of 1, 10 and $100{\mu}g/ml$. For the effect of NO production, Haeyeol-tang showed significant (p<0.001) decrease of NO production, according to its concentration. For the effect on the eliminating activity of DPPH radical, Haeyeol-tang showed increasing tendency of eliminating activity of DPPH radical, according to its concentration. For the effect on revelation of NOS2 enzyme, Haeyeol-tang showed inhibiting tendency against the revelation of NOS2, according to its concentration. For the effect on the TNF-$\alpha$ production, Haeyeol-tang showed significant (p<0.001) decrease of TNF-$\alpha$ production. Conclusions : This result means that Haeyeol-tang is effective for anti-inflammation, as well as excellent effect for anti-oxidation and anti-aging.

• BMB Reports
• /
• v.51 no.11
• /
• pp.545-546
• /
• 2018

With emerging evidence on the importance of non-cell autonomous toxicity in neurodegenerative diseases, therapeutic strategies targeting modulation of key immune cells. including microglia and Treg cells, have been designed for treatment of ALS and other neurodegenerative diseases. Strategy switching the patient's environment from a pro-inflammatory toxic to an anti-inflammatory, and neuroprotective condition, could be potential therapy for neurodegenerative diseases. Mesenchymal stem cells (MSCs) regulate innate and adaptive immune cells, through release of soluble factors such as $TGF-{\beta}$ and elevation of regulatory T cells (Tregs) and T helper-2 cells (Th2 cells), would play important roles, in the neuroprotective effect on motor neuronal cell death mechanisms in ALS. Single cycle of repeated intrathecal injections of BM-MSCs demonstrated a clinical benefit lasting at least 6 months, with safety, in ALS patients. Cytokine profiles of CSF provided evidence that BM-MSCs, have a role in switching from pro-inflammatory to anti-inflammatory conditions. Inverse correlation of $TGF-{\beta}1$ and MCP-1 levels, could be a potential biomarker to responsiveness. Thus, additional cycles of BM-MSC treatment are required, to confirm long-term efficacy and safety.

• Molecular & Cellular Toxicology
• /
• v.5 no.1
• /
• pp.93-98
• /
• 2009

Stephania delavayi Diels. has been used as an immune activator or an anti-inflammatory drug in China. We examined the immune modulation effect and 7-days repeated-dose toxicity to validate its biological safety and efficiency. Mice were repeatedly administrated with 50 mg/kg S. delavayi Diels. daily by I.P for 7 days. S. delavayi Diels. induced B cell activation but had no effect on other immune cells such as T cell, natural killer (NK) cell, and macrophage ($M{\varphi}$). S. delavayi Diels.-treated group exhibited no statistical significance from the control group in physical conditions; body weight, complete blood count (CBC), serum biochemical indexes etc. There was no difference between the control group and S. delavayi Diels.-treated group in gross findings such as histopathological alteration. In conclusion, S. delavayi Diels. is safe above the dose of immune modulation.